A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

November 16, 2026 updated by: Eli Lilly and Company

A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.

Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

617

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

      • Singapore, Singapore, 138623
        • Not yet recruiting
        • Lilly Centre for Clinical Pharmacology
        • Contact:
          • Phone Number: 64139811
        • Principal Investigator:
          • Jennifer Boon Wee
    • Arkansas
      • Rogers, Arkansas, United States, 72758
        • Not yet recruiting
        • Woodland Research Northwest, LLC
        • Contact:
          • Phone Number: 479-927-3000
        • Principal Investigator:
          • Timothy Cook
    • California
      • Anaheim, California, United States, 92801
        • Recruiting
        • CenExel ACT
        • Principal Investigator:
          • Amina Haggag
      • Los Alamitos, California, United States, 90720
        • Recruiting
        • Collaborative Neuroscience Network - CNS
        • Principal Investigator:
          • Steven Reynolds
      • Walnut Creek, California, United States, 94598
        • Recruiting
        • Diablo Clinical Research, Inc.
        • Principal Investigator:
          • Bonnie Kimmel
    • Florida
      • Daytona Beach, Florida, United States, 32117
        • Recruiting
        • Fortrea Clinical Research Unit
        • Contact:
          • Phone Number: 866-429-3700
        • Principal Investigator:
          • Chiamaka Iheme
      • Miami, Florida, United States, 33417
        • Not yet recruiting
        • Advanced Pharma CR, LLC
        • Principal Investigator:
          • Simon Abelson
      • Winter Park, Florida, United States, 32789
        • Recruiting
        • Clinical Site Partners, LLC DBA CSP Orlando
        • Principal Investigator:
          • ROBERT MEYER
    • Georgia
      • Columbus, Georgia, United States, 31904
        • Recruiting
        • Centricity Research
        • Principal Investigator:
          • Joseph Surber
        • Contact:
          • Phone Number: 706-321-0495
      • Decatur, Georgia, United States, 30030
        • Recruiting
        • CenExel iResearch, LLC
        • Principal Investigator:
          • Kimball Johnson
    • Missouri
      • Springfield, Missouri, United States, 65802
        • Recruiting
        • QPS
        • Principal Investigator:
          • Leea Reed
        • Contact:
          • Phone Number: 417-893-6161
    • New Jersey
      • Marlton, New Jersey, United States, 08053
        • Recruiting
        • CenExel-HRI
        • Principal Investigator:
          • Kyle Coupe
    • Ohio
      • Columbus, Ohio, United States, 43212
        • Recruiting
        • Ohio Clinical Trials
        • Principal Investigator:
          • Angela Eakin
    • Texas
      • Dallas, Texas, United States, 75247
        • Recruiting
        • Fortrea Clinical Research Unit
        • Principal Investigator:
          • Archie Bowie
      • San Antonio, Texas, United States, 78217
        • Recruiting
        • Worldwide Clinical Trials, Inc.
        • Principal Investigator:
          • Alan Hand

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants must be 21 in Singapore.
  • Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.

Part A, B, D, and E

  • Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:

    • hypertension
    • dyslipidemia
    • obstructive sleep apnea, or
    • prediabetes.

Part C

  • Have a BMI ≥25.0 kg/m²
  • Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
  • T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
  • Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.

Part D

  • To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.

Part E

  • To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.

Exclusion Criteria:

  • Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A: LY4167586

LY4167586 administered subcutaneously (SC)

administered SC

Experimental: Part B LY4167586

LY4167586 administered SC

administered SC

Experimental: Part C LY4167586

LY4167586 administered SC

administered SC

Experimental: Part D LY4167586

LY4167586 administered SC

administered SC

Experimental: Part E LY4167586

LY4167586 administered SC

administered SC

Placebo Comparator: Placebo (Part A-E)

Placebo administered SC

administered SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline through Study Completion (Estimated as Week 89)
Baseline through Study Completion (Estimated as Week 89)

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
Time Frame: Baseline up to Week 89
Baseline up to Week 89
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
Time Frame: Baseline up to Week 89
Baseline up to Week 89
Body Weight Observed Value
Time Frame: Baseline up to Week 89
Baseline up to Week 89
Change from Baseline in Body Weight
Time Frame: Baseline up to Week 89
Baseline up to Week 89
Percent Change from Baseline in Body Weight
Time Frame: Baseline up to Week 89
Baseline up to Week 89

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2026

Primary Completion (Estimated)

March 1, 2029

Study Completion (Estimated)

March 1, 2029

Study Registration Dates

First Submitted

October 13, 2026

First Submitted That Met QC Criteria

October 13, 2026

First Posted (Actual)

October 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27671
  • J6L-MC-YIAB (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.